U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07665879) titled 'A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity' on June 19.
Brief Summary: The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in participants with obesity or overweight. For each participant, the study will last about 35 weeks and include 3 in patient visits totaling 7 days.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Overweight
Obesity
Intervention:
DRUG: Eloralintide
Eloralintide administered SC
O...